Bone Drugs May Not Help Women Long Term, FDA Review Says

Bone-strengthening drugs such as Merck & Co. (MRK)’s Fosamax, used to treat and prevent osteoporosis in older women, may have little long-term benefit, U.S. regulators said in an analysis of previously released studies. Research from the Food and Drug Administration, published yesterday in the New England Journal of Medicine, renews a debate about whether use of the drugs after more than three to five years provides any protection against the risk of bone fractures.

Read more about the NEJM findings on Fosamax…

0 Responses to “Bone Drugs May Not Help Women Long Term, FDA Review Says”

  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 435 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101


Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.

%d bloggers like this: